Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.45%201.801.2%$542.05m
GILDGilead Sciences, Inc.
-1.21%73.270.9%$465.10m
BIIBBiogen Inc.
-2.95%320.411.3%$380.15m
CELGCelgene Corporation
-0.65%82.411.2%$337.48m
ILMNIllumina, Inc.
-2.60%313.103.5%$332.96m
REGNRegeneron Pharmaceuticals, Inc.
-1.36%389.832.6%$235.91m
VRTXVertex Pharmaceuticals Incorporated
-1.79%175.691.9%$230.46m
ALXNAlexion Pharmaceuticals, Inc.
-0.53%125.892.0%$220.48m
SRPTSarepta Therapeutics, Inc.
-3.30%134.2216.4%$169.84m
AAgilent Technologies, Inc.
-1.95%64.471.5%$159.28m
BMRNBioMarin Pharmaceutical Inc.
-0.58%103.224.4%$142.60m
LGNDLigand Pharmaceuticals Incorporated
-4.84%187.5223.3%$115.84m
EXASExact Sciences Corporation
-2.88%61.6425.3%$102.69m
NKTRNektar Therapeutics
-2.76%48.195.6%$101.86m
NBIXNeurocrine Biosciences, Inc.
-2.24%112.015.1%$98.21m

Company Profile

Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.